Alzamend Neuro has completed a study comparing AL001 and lithium carbonate in Alzheimer's mice, showing potential advantages of AL001 at low doses. This could offer safer long-term treatment options for conditions like Alzheimer's. ALZN stock rose 6.67% to $1.44.